WPD Pharmaceuticals Welcome Dr. Waldemar Debinski to its Scientific Advisory Board

Dr. Debinski is the inventor of WPD101, WPD102 and WPD103 drug candidates and holds over 25 patents on various cancer fighting solutions

VANCOUVER, British Columbia, April 01, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, is excited to announce that Dr. Waldemar Debinski, inventor of WPD101, WPD102 and WPD103 drug candidates has joined its Scientific Advisory Board. The Company’s name comes from the names of inventors Dr. Waldemar Priebe and Dr. Waldemar Debinski, which creates the “WPD” in WPD Pharmaceuticals.

Mariusz Olejniczak, CEO of WPD commented, “Not only is Dr. Debinski an exceptional scientist, he’s also the inventor of WPD101, WPD102 and WPD103 drug candidates of the WPD portfolio, and we are thrilled to welcome him to our scientific advisory board. Dr. Debinski joins our esteemed scientific team of experts and his experience and knowledge of researching and developing drug candidates will be extremely valuable as we continue to advance our portfolio of anti-cancer therapies. Adding Dr. Debinski to our board also establishes a stronger partnership with Wake Forest School of Medicine, which owns Dr. Debinski’s inventions that are licensed by WPD, and we look forward to continued collaboration with their world class research team.”

About Waldemar Debinski

Waldemar Debinski, MD, PhD, is the Tom and Laura Hearn Professor for the Brain Tumor Center of Excellence and Director of the Brain Tumor Center of Excellence, Wake Forest Baptist Medical Center Comprehensive Cancer Center, and professor of cancer biology, radiation oncology, Microbiology and immunology, and Translational Science Institute at Wake Forest School of Medicine. He has pioneered the discovery and use of targets in malignant brain tumor cells that are not present in a healthy brain to destroy them effectively and safely. With a broad range of expertise and experience in both basic science and preclinical models, he develops novel approaches to drug development and delivery and partners with industry for both therapeutic licensing and testing purposes.

Dr. Debinski holds twenty-five patents on various therapeutics and other cancer-fighting solutions, including a drug candidate that uses specific molecular targets to treat glioblastoma while also being less toxic than radiation and chemotherapy and less invasive than surgery.

Dr. Debinski also partners with researchers at the Virginia Tech – Wake Forest University School of Biomedical Engineering and Sciences to develop a new method of drug delivery called convection-enhanced delivery. This method has the potential to make brain tumors more accessible to doctors by assisting chemotherapeutics and experimental drugs in bypassing the blood-brain barrier, the main obstacle to successful drugs delivery to brain tumors.